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Available online xxxxCertain inborn errors of metabolism have been suggested to increase the risk of autistic behavior. In an animal
model, propionic acid ingestion triggered abnormal behavior resembling autism. So far only a few caseswere re-
portedwith propionic acidemia and autistic features. From a series of twelve consecutively diagnosed caseswith
propionic acidemia, we report on eight patients with autistic features.
The patients were followed 2–4 times a year and underwent regular clinical, dietary and laboratory investiga-
tions. Psychological evaluation was performed every second to fourth year.
All patients were compliant with the standard diet and carnitine supplementation. None of the patients had fre-
quentmetabolic decompensations. From themetabolic factors known to impact neuropsychological outcomewe
detected chronically decreased valine levels and altered valine to leucine ratios in ﬁve out of the eight patients.
Recurrent lactic acid elevations were present in six out of the eight patients. Five of the eight patients were diag-
nosedwith Autism SpectrumDisorder, four of themhad pathogenic variants in PCCB. Disorder according to DSM-
IV and/or DSM-5 criteria. One of the patients diagnosed with propionic acidemia by newborn screening had the
most signiﬁcant behavioral features and another was diagnosed with Autism Spectrum Disorder prior to
propionic acidemia.
We hypothesize that chronic suboptimal intracellular metabolic balance may be responsible for the increased
risk for autistic features in propionic acidemia. We propose that patients diagnosed with propionic acidemia
should be screened for Autism Spectrum Disorder.
© 2016 Elsevier Inc. All rights reserved.Keywords:
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Propionic acidemia (PA) is a severe organic acidemia, characterized
by acute episodes of metabolic acidosis, ketosis, lactic acidemia,
hyperammonemia, lethargy, basal ganglia involvement, and seizures.
Even well treated patients might develop growth delay, developmental
and speech delay. Long term outcome is often characterized by intellec-
tual disability [1,2]. Recurrent episodes of pancreatitis,muscleweakness
and metabolic cardiomyopathy occur in a high percentage of cases, es-
pecially in those with insufﬁcient therapeutic compliance [3]. Even the
most adequately treated patients might develop neurologic symptomsr, Tulane University School of
s, Metabolic Center, University
a).
utism in patients with propiincluding psychomotor retardation, speech delay, dystonia and even is-
chemic strokes of the basal ganglia [2]. Behavioral changes are relatively
common in adolescent patients with PA, though Autism Spectrum Dis-
order (ASD) has been only reported in a single patient.
ASD is a complex neurodevelopmental disorder, characterized by so-
cial impairments, communication difﬁculties, and restricted, repetitive,
and stereotyped patterns of behavior. Several inborn errors of metabo-
lismhave been described as increasing a patient's risk for ASD, including
lysosomal storage diseases, disorders of the creatine synthesis, disor-
ders of purine and pyrimidine metabolism or dysfunction of the urea
cycle, but autistic features are not frequently reported in organic
acidemias [5,8,9,10,11]. With the growing frequency of patients being
diagnosed with ASD, sometimes it is difﬁcult exclude a coincidental di-
agnosis of autism in certain metabolic conditions from comorbidity, es-
pecially in case of intellectual disability. The incidence of metabolic
disorders in autistic patients is not known, but is estimated as high asonic acidemia, Mol. Genet. Metab. (2016), http://dx.doi.org/10.1016/
2 P. Witters et al. / Molecular Genetics and Metabolism xxx (2016) xxx–xxx5%, while in the general population cumulative occurrence of inborn er-
rors of metabolism is closer to 1 in 8005. In recent guidelines for the
treatment of propionic acidemia, evaluation and monitoring for autism
is not yet included [2].
Interestingly, studies evaluating the effects of elevated propionic
acid in rats have suggested a possible connection with autism [6,7].
Propionic acid administered systemically or by intracebro-ventricular
injection to adult rats produced a rapid induction of repetitive move-
ments, hyperactive activity, and seizure activity alongwith neuro-path-
ological and biochemical similarities to human ASD [6]. The
mechanisms by which elevated levels of propionic acid affect the CNS
are unknown, but possible candidates include interference with cellular
metabolism, increased inﬂammatory cytokines and the reduction of in-
tercellular gap-junctional communication.
Herewe report on eight patientswith autistic features and propionic
acidemia from a case series of twelve consecutively diagnosed propionic
acidemia patients. Biochemical and clinical information was collected
and evaluated whether a risk factor for autism could be found.
2. Methods
2.1. Patient selection
A total of eight patients with propionic acidemia (PA) were evaluat-
ed in detail in this study. The inclusion criteria were the biochemicalTable 1
Clinical and genetic information in eight patients with features of the autistic spectrum, out of
were not included in the analysis due to insufﬁcient detail on neurodevelopmental and bioche
Patient Sex Age
(years)
Diagnosis eMetabolic
crises/year
Motor
delay
Intellectual
disability
Speech
develop
1. M 3c NBS 2 Mild N/A Absent
2. M 4 NBS 2–3 Severe Moderate Absent
3.b M 4 NBS 0 Moderateh Moderate Absent
4.a M 7 3 years 0 None None Delayed
5. M 8 7 days 2–3 Moderate Moderate Delayed
6.a M 11 2.5 months 1–2 Mild Moderate Delayed
7.a M 11 NBS 2–3 Mild Mild Delayed
8.a F 21 3 months 1 Moderate Moderate Delayed
Patients with insufﬁcient data for analysis
9. M 9 5 years 0 None None Norma
10. M 7 5 days 1–2 None None Delayed
11. M 3c 3 years NA None None Norma
12. F 4c 10 days 2–4 Severe N/A Absent
NBS denotes newborn screening test positive for Propionic academia.
Patients 6 and 7 are fraternal twins, patients 4 and 9 and Patient 10 and 11 were brothers.
a Diagnosis of autism (ASD) according to DSM-IV (Lord et al., Autism Diagnostic Observation
b Diagnosis of autism (ASD) according to DSM-5 criteria (Sparrow, Cicchetti, Balla, Vineland
c Patient deceased.
d Propionic acidemia related early coma episode.
e Number of metabolic disarrangements in the ﬁrst 4 years of life.
f Central hypotonia.
g Previously described mutations in all but one patient (Kraus et al., J Inherit Metab Dis (201
1990, 8:249).
h So far unreported, predicted pathogenic variant.
Please cite this article as: P. Witters, et al., Autism in patients with propi
j.ymgme.2016.10.009diagnosis of propionic acidemia conﬁrmed in ﬁbroblasts, in two centers,
between 1995 and 2015. Twelve patients were diagnosed during the
twenty years period. Four patientswere excluded from thedata analysis
due to the unavailability of sufﬁcient detailed clinical/metabolic and be-
havioral data. The patients' age range was between 3 and 20 years, with
amedian age of 7.5 years. Patients 6 and 7 are fraternal twins, patients 4
and 9 and Patient 10 and 11 were brothers. Seven patients were male,
and one was female (Table 1). With regards to therapy, all of the pa-
tients followed a strict protein-restricted diet, with amaximumdaily in-
take of 0.8–1 g/kg/day of natural protein and high caloric intake (110–
138 cal/kg/day). All patients received carnitine (50–100 mg/kg/day)
and biotin (10 mg/day) supplements. All but one patient received
amino acid based metabolic formula, free of the precursor amino acids
(Met, Val, ILe, Thr) additional to protein-free metabolic formula with
extra sources of calories through carbohydrates and fats.2.2. Prognostic factors
Prognostic factors known to play a role in PA patients' long-term
outcome were retrospectively evaluated in our cohort. We included
clinical, neurologic, and neuropsychiatric features, disease history and
disease severity, anomalies on brain imaging, developmental features,
behavioral problems, the presence of autistic features or the diagnosis
of Autism Spectrum Disorder, and metabolic laboratory values ina twelve patients' cohort diagnosed with propionic acidemia (four patients; Patient 9–12
mical data).
ment
CNS
involvement
Basal ganglia
involvement
Organ
involvement
gPathogenic variants
(cDNA and protein)
Hypotoniaf Infantile None PCCB c.1209+3AN
G/p.V356E403del
c.1209+3AN
G/p.V356E403del
Hypotoniaf Neonatal None PCCB c.562GNA/p.G188AR
c.562GNA/p.G188R
None None None PCCB c.638CNT/p.P228L
c.638CNT/p.P228L
None None None PCCB c.683delC/p.P228L
c.683delC/p.P228L
Noned None None PCCA c.1891CNG/p.G631R
c.1891CNG/p.G631R
Abnormal
gaitd
None None PCCB
c.1218_1231del14ins12
p.G407Rfs*14
and hc.479ANG p.D160G
Abnormal
gait
None Arrhythmia PCCB
c.1218_1231del14ins12
p.G407Rfs*14
and hc.479ANG p.D160G
Spasticityd None Pancreatitis N/A
l None None None PCCB c.683delC/p.P228L
c.683delC/p.P228L
None None None PCCB c.1210GNA p.E404K
c.1210GNA p.E404K
l None None Pancreatitis PCCB c.1210GNA p.E404K
c.1210GNA p.E404K
Hypotonia None Pancreatitis PCCA c.923dupT/p.L308fs
c.923dupT/p.L308fs
Schedule (ADOS-2), 2nd Ed. 2000).
Adaptive Behavior Scales-2nd Ed. 2005).
2) 35:51–63; Perez et al., Mol Genet Metab 2003,78: 59; Lamhownwah et al., Genomics.
onic acidemia, Mol. Genet. Metab. (2016), http://dx.doi.org/10.1016/
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ment two to four times a year depending on their age.2.3. Metabolic and genetic factors
Westudied thedifferent clinical and biochemical parameters used to
monitor the course of propionic acidemia in eight patients from a case
series of twelve consecutively diagnosed propionic acidemia patients,
treated from 1995 till present. Biochemical parameters included blood
levels of lactate, amino acids (with focus on alanine, isoleucine, leucine,
valine, and methionine), ammonia, plasma C3 acyl-carnitine and
methylcitrate and OH-propionate in the urine. Clinical data included
the age and type of diagnosis, disease history, treatment history, multi-
system involvement andMRI changes. Except for in one patient DNA se-
quence analysis was requested.2.4. Neuro-psychological evaluation
Developmental assessment is systematically implemented in the
multidisciplinary follow-up of metabolic patients and contains a multi-
disciplinary assessment at the age of 1 year; 2,5 years; 6 years and
12 years. Age-adapted instruments are used such as: Bayley Scales for
infant development II (BSID-II), Wechler Preschool and Primary Scale
of Intelligence III NL (WPPSI II-NL) and Wechsler Intelligence Scale for
Children III-NL (WISC III-NL) for assessment of mental development
and the Reynell Developmental Language Scales and Dutch Non-Speech
Test for assessment of language development. The Peabody Develop-
mentalMotor Scales second editionwas used to assessmotor capacities.
Because some of the patients were unable to cooperate with age-appro-
priate intelligence measures at the 4 year visit, the Bayley Scales of In-
fant and Toddler Development-3rd Edition (BSID-3; Bayley, 2006) was
administered to calculate age equivalents only. Categorization of intel-
lectual disability was done according to the ICD-10 categorization sys-
tem (Table 2, Supplementary Tables 1 and 2).
When the possibility of ASDwas assumed based on clinical observa-
tions in our Europeanpatients, a referralwasmade to a specialized diag-
nostic center for further neuropsychiatric studies. Diagnostic methods
contained a semi-structured interview with parents, play observation,
class observation, evaluation by a speech therapist, and questionnaires
for parents and teachers. In the American patients ASD was evaluated
by data gleaned through a detailed developmental interview, adminis-
tration of the appropriatemodule of the Autism Diagnostic Observation
Schedule, Second Edition (ADOS-2) and the Vineland adaptive behavior
measure (Tables 1 and 2).Table 2
Intellectual disability assessment in eight patients with autistic features.
Patient nr Sex Eval. age Instruments Outc
Patient 1 M 20 months Peabody scale Deve
Patient 2 M 20 months BSID-II NL Deve
25 months BSID-II NL Deve
30 months BSID-II NL Deve
Patient 3 M 26 months Adaptive Behavior Scale Deve
56 months BSID-3 Deve
56 months Deve
Patient 4 M 4 years School admission Atten
Patient 5 M 4 years Wechsler 60B
Patient 6 M 66 months SON-R SON-
Patient 7 M 66 months Tandem /
Patient 8 F 6 years Wechsler 52EL
SON-R, Snijers-Oomen nonverbal intelligence test-Revised; BSID-II NL, Bayley Scales of Infant D
Vineland Adaptive Behavior Scale 2nd Edition Sparrow et al., 2005.
Bayley Scales of Infant and Toddler Development-3rd Edition (BSID-3; Bayley, 2006).
Wechsler Intelligence Scale for Children: A average, LA low average, B borderline, EL extremely
Please cite this article as: P. Witters, et al., Autism in patients with propi
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3.1. Clinical course and prognosis
Of the twelve patients we studied, eight had sufﬁcient information
for this retrospective study. These were also the patients who showed
autistic features. Of these eight patients ﬁve were diagnosed in the neo-
natal period. Four presented with positive newborn screens and mini-
mal symptoms. One had clinical symptoms before newborn screening
results. The remaining 3 patients presented between 2.5 months and
three years with symptoms of a metabolic coma and were clinically di-
agnosed (Table 1). Five of the patients continued to have recurrentmet-
abolic decompensations requiring hospital admissions yearly. All
patients were compliant with treatment, followed the prescribed diet
and took dietary supplements. One of the patients had up to 3 exacerba-
tions yearly. Interestingly, one of the patients later diagnosed with ASD
had no metabolic crises or episode of coma during the clinical course.
One patient had a transient cardiac involvement (a rhythm abnormality
with long QT syndrome) and one patient had episodes of pancreatitis.
None of the patients with ASD had systemic organ involvement at the
time of analysis.3.2. Metabolic parameters
Metabolic parameterswere evaluated to look for possible abnormal-
ities, which could be associated with autistic features in PA.We used 85
pooled data points from individual blood sampling moments and urine
collection data.
Recurrent lactic acidemiawas present in 35% of themeasured lactate
levels (30/85) in the patients. No chronic lactic acidemia was noted in
any of the children. Elevated blood alanine levels were sporadic, in
9.4% of the data points. Blood isoleucine levels were almost all normal,
with 8% low normal, but within the normal range. Leucine levels were
also almost always normal, with less the 5% low normal. Interestingly
70% of the biochemical values (60/85) showed decreased valine levels,
(mean 62, range 10–150) (control 100–480 mmol/l) (Supplementary
Fig. 1). The mean valine/leucine ratio using all pooled data points was
1.3 (ranged between 0.9 and 1.5, control range 1.5–2). Only 5% of the
patient's data showed a low methionine level. From the pooled patient
data 40% (34/85) showed an elevated ammonia level, with the highest
level at 200 μmol/l (control range b 35 μmol/l) but none had a chronic
elevation. None of the patients had chronically elevated glutamine
levels.
None of the patients had C3 carnitine levels above 10 μmol/l
(control b3.3 μmol/l) or methylcitrate levels above 200 mmol/mmolome Developmental age Intellectual disability
lopmental index b75 16 months N/A Autistic
lopmental index b55 5.5 months Moderate Autistic
lopmental index b55 6 months Moderate
lopmental index b55 6.5 months Moderate
lopmental index b70 18 months Mild ASD
lopmental index b60 34 months Moderate
lopmental index b55 22 months Moderate
ds regular school Age appropriate None ASD
2.5 years Moderate Autistic
IQ = 50 36 months Moderate ASD
21 months Mild ASD
3 years Moderate ASD
evelopment 2nd edition Dutch version.
low.
onic acidemia, Mol. Genet. Metab. (2016), http://dx.doi.org/10.1016/
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after the initial diagnosis.
3.3. Mutation analysis
Results were available in 11 patients from the total cohort, and in 7
out of the 8 patients studied in detail. The following known pathogenic
variants were detected: in the PCCA gene in Patient 1 a homozygous
c.1209+3ANG; p.V356E403del and in Patient 5 homozygous
c.1891CNG; p.G631R, without autistic features. In the PCCB gene the
c.638CNT; p.P228L known pathogenic variant was found in Patient 3,
Patient 4 and Patient 9 in homozygous form, and c.562GNA; p.G188R
known pathogenic variant in Patient 2.
Patients 3 and 4 were diagnosed with autism. Patient 4 and 9 were
brothers. Although in Patient 9 only insufﬁcient data was available for
metabolic analysis, he had a normal development, attended regular ed-
ucation and no autistic features.
Compound heterozygous known variants in PCCB were detected in
the fraternal twins, both known with autism (c.1218_1231del14ins12;
p.G407Rfs*14/c.479ANG; p.D160G). In summary all patients with au-
tism had a pathogenic variant in PCCB. The available variants andmuta-
tion references are depicted in Table 1.
3.4. Neuro-psychological features
Neurologic involvement was quite variable in the cohort. Two of the
patients had a fully normal motor development. Several patients had
mild tomoderate motor delay, andmost patients hadmild to moderate
intellectual disability. Only one patient had normal intelligence. One of
the ﬁve patients (Table 1) was diagnosed with ASD ﬁrst, before the di-
agnosis of PA was established. Other neurologic features included ab-
sent speech in three, hypotonia in two, abnormal gait in two, and
spasticity in the oldest, female patient. One patient had transient abnor-
malities at the age of 3 months by MRI imaging. The other patient, the
youngest of the cohort, also showed basal ganglia involvement with ab-
normal signal intensity of the caudate nuclei on CT. The two patients
with basal ganglia involvement were not the ones who had a formal di-
agnosis of ASD. None of the patients showed any clinical regression dur-
ing the course of the disease.
Autistic features were present in all the patients including repetitive
movements or hand ﬂapping, ritualistic behavior, stereotypic behavior
(three patients), abnormal social interaction (seven patients), commu-
nication difﬁculties (all patients), and inﬂexibility in planning (all pa-
tients). Four patients were diagnosed with an Autism Spectrum
Disorder between the age of 2 and 5 years. One patient was diagnosed
with ASD at 2.5 years before the diagnosis of PA. In summary autistic
features were present in all eight patients, with ﬁve having the formal
ASD diagnosis, four of which were diagnosed between 2 and 5 years,
and onewas diagnosed even before diagnosedwith PA (Tables 1 and 2).
4. Discussion
While the etiologic factors in most patients with symptoms in the
autistic disorder spectrum are not fully understood, changes in amino
acid metabolism and organic acid concentrations have been reported
in animal models mimicking autistic symptoms [6,7]. Furthermore,
amino acid levels in autistic patients have been reported as signiﬁcantly
different from non-autistic control groups [3,5,14]. Inborn errors of me-
tabolism such as propionic acidemia have been suggested to increase
the risk for autism in a few cases [4,18]. Interestingly in another case re-
port partial biotinidase deﬁciency, leading among others to decreased
activity of propionyl-CoA carboxylase, the defective enzyme in PA,
could also cause ASD [13]. We evaluated eight PA patients with autistic
features and investigated their biochemical and metabolic control, diet,
and their clinical history.Please cite this article as: P. Witters, et al., Autism in patients with propi
j.ymgme.2016.10.009We hypothesized that patients with early diagnosis, treatment, and
good clinical and metabolic management will be less likely to develop
neurologic and neuropsychological features, including autistic features
or ASD in propionic acidemia. Early diagnosis, however did not seem
to have a fully preventive effect on a complicated behavioral outcome.
One of the patients diagnosed with propionic acidemia by NBS and
with ASD has never had metabolic crises, or coma episodes during the
clinical course. None of the patients diagnosed with ASD had systemic
organ involvement, or basal ganglia involvement, which are known to
correlate with insufﬁcient metabolic control. In general, however, pa-
tients with a later diagnosis and recurrent metabolic decompensations
were more frequently diagnosed with developmental delay and also
with ASD.
Propionic acidemia is a metabolic disorder that affects not only the
branched chain amino acid and odd chain fatty acid degradation but
also has a negative effect on the normal function of both the urea
cycle and the citric acid cycle, and can lead to neurotransmitter imbal-
ance, and abnormal energy metabolism [3]. In our patient cohort 30–
40%of thepooledmetabolic data showed elevated lactate andor ammo-
nia levels, without chronic lactic acidemia or hyperammonemia. Lactic
acid elevation is a common metabolic sign in many patients with ASD.
Mitochondrial dysfunction, a known consequence of propionic
acidemia, has also been associated with autism [12]. Hyperammonemia
has been associatedwith autistic features inmild, or insufﬁciently treat-
ed urea cycle disorder patients. Although some of the metabolic results
we describe were collected during metabolic decompensation periods
and do notmirror the generalmetabolic balance, we propose that mito-
chondrial involvement could play a signiﬁcant role in the development
of autistic features.
Physiologic blood and CSF amino acid concentrations are essential
for normal neurodevelopment. Several studies on amino acid levels in
ASD patients demonstrated signiﬁcant changes in amino acid concen-
trations, like lowmethionine or high alanine levels [14]. In our small co-
hort we could not conﬁrm these amino acid concentration changes.
However, we did ﬁnd a very interesting alteration, low normal serum
valine levels and a decreased valine to leucine ratio, detected in thema-
jority of our patients. Similar results have been previously documented
in PA [15] and MMA and may be a consequence of supplementation
with leucine enriched, precursor free amino acid mixture (Manoli et
al., Genetics in Med 2016). Additionally, the primary enzymatic defect
affects intra-mitochondrial physiologywhich, in the neuron, is impossi-
ble to monitor with standard metabolic methods.
A normal valine to leucine ratio is important for branch-chained
amino acid (BCAA) transport through the blood brain barrier and for
normal neurotransmitter concentrations. Abnormal BCAA transport
has been suggested to lead to abnormal psychological development in
other disorders such as Maple Syrup Urine Disease [8]. Some of the ob-
served changes in BCAA ratios might be a consequence of the use of
amino acid based metabolic formulas that are free of the amino acids,
valine, methionine, isoleucine and threonine in PA patients.
No genotype phenotype analysis was possible in our small cohort.
However, interestingly all patients diagnosed with autism and an avail-
able mutation result had a pathogenic variant in PCCB. There was one
particular mutation, found in homozygous state in two unrelated pa-
tients with the diagnosis of autism. Both patients had a mild metabolic
phenotype, and no recurrentmetabolic crises. However the samemuta-
tion was found in the brother of one of these patients, without develop-
mental delay, metabolic crises and without any autistic features.
There are several different inborn errors of metabolism, where the
associated ASD has been hypothesized to correlate with a
neurodevelopmental defects and congenital brain anomalies, like con-
genital disorders of glycosylation (CDG) or Smith Lemli Opitz syndrome
[9,10]. However, no similar brain abnormalities have been observed in
our patients with PA. Basal ganglia involvement is also associated with
higher frequency of autistic features, but we didn't ﬁnd correlation be-
tween basal ganglia abnormalities and ASD in our small cohort [16].onic acidemia, Mol. Genet. Metab. (2016), http://dx.doi.org/10.1016/
5P. Witters et al. / Molecular Genetics and Metabolism xxx (2016) xxx–xxxFour of our ﬁve patients diagnosed with ASD had a mild or moderate
motor delay and intellectual disability (Table 1). One should also em-
phasize that in the general population intellectual disability has 75% co-
morbidity with autism [17]. However in our cohort, patients without
intellectual disability also showed autistic features or ASD. The current
data presented would indicate an ASD prevalence higher than the 1 in
68 in the general population (CDC, 2016), suggesting a higher incidence
of ASD in the PA population. The American Academy of Pediatrics sug-
gests routine screening of children at 18 and 24months or when a care-
giver and/or physician raises a concern. PA has neurodevelopmental
implications that can be similar to the symptoms observed in ASD
(i.e., intellectual disability, language delays), which makes screening
an important element in the care of an individual with PA.
Previous studies on amino acid analysis in ASD demonstrated di-
verse changes in levels of different amino acids, which could represent
comorbidities, like nutritional deﬁciencies, or signs of mitochondrial
dysfunction, but could also represent metabolic phenotypes, and bio-
markers for ASD [14]. This has been also suggested in several publica-
tions evaluating the possible correlation between gastrointestinal
propionic acid production and autism [18]. Abnormal branch chained
amino acid ratios have also been correlatedwith poor neuropsychologic
outcome [8].With the increasing reported frequency of ASD in the pedi-
atric population one cannot rule out a possible coincidence of the diag-
nosis of ASD in patients with propionic acidemia [19]. Given a
population autism rate of approximately 0.005, the chance of this occur-
ring with no connection with PA is 4.34 × 10−13. In our case series ﬁve
out of eight propionic acidemia patients exhibited autism, strengthen-
ing the possible correlation between propionic acidemia and ASD.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ymgme.2016.10.009.
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